A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors | Zendy

Bishal Gyawali | Zendy; Spencer Phillips Hey | Zendy; Aaron S. Kesselheim | Zendy

Open Access

A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors

Author(s) -

Bishal Gyawali,

Spencer Phillips Hey,

Aaron S. Kesselheim

Publication year - 2018

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2018.0416

Subject(s) - nivolumab , pembrolizumab , medicine , oncology , hazard ratio , ipilimumab , randomized controlled trial , clinical trial , progression free survival , meta analysis , cancer , overall survival , confidence interval , immunotherapy

Key Points Question Does the treatment effect size differ between overall survival and progression-free survival for PD-1 (programmed cell death 1) inhibitors used in patients with advanced solid tumors, and are overall survival and progression-free survival correlated? Findings This meta-analysis of 12 randomized clinical trials found no significant correlation between overall survival and progression-free survival in terms of medians and gains in medians, but their hazard ratios were significantly correlated. The protective effects of treatment were greater for overall survival than for progression-free survival. Meaning Progression-free survival cannot adequately capture the benefit of PD-1 inhibitors; thus, overall survival should remain the gold standard end point for trials of PD-1 inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research